PGE1及特利加压素对抗利尿性腹腔积液的影响
投稿时间:2015-12-09  修订日期:2016-01-11  点此下载全文
引用本文:刘远志,李鹏,张月宁,丁惠国,张世斌.PGE1及特利加压素对抗利尿性腹腔积液的影响[J].医学研究杂志,2017,46(1):104-108
DOI: 10.11969/j.issn.1673-548X.2017.01.029
摘要点击次数: 908
全文下载次数: 796
作者单位E-mail
刘远志 100069 首都医科大学附属北京佑安医院消化中心一科  
李鹏 100069 首都医科大学附属北京佑安医院消化中心一科  
张月宁 100069 首都医科大学附属北京佑安医院消化中心一科  
丁惠国 100069 首都医科大学附属北京佑安医院消化中心一科  
张世斌 100069 首都医科大学附属北京佑安医院消化中心一科 zhangshibin0002@sina.com 
中文摘要:目的 探究前列腺素E1联合特利加压素对肝硬化难治性腹腔积液患者肾功能、血流动力学、心率等相关指标的影响。方法 将50例肝硬化难治性腹腔积液分为两组,联合治疗组25例,应用前列腺素E1联合特利加压素;对照组25例,只用前列腺素E1。特利加压素1mg,每8h 1次,静脉注射。前列腺素E1 10μg,每天1次,静脉注射。比较两组患者尿量、腹围、血肌酐等指标变化。结果 治疗前两组患者体重、性别、白蛋白等基本信息比较,差异无统计学意义(P>0.05)。两组患者治疗后较治疗前BUN与SCr均明显下降,差异有统计学意义(P<0.05),且治疗后,联合治疗组SCr明显低于对照组,差异有统计学意义(t=-2.199;P=0.033)。两组患者治疗后较治疗前腹腔积液减少、尿量增多,差异有统计学意义(P<0.05);治疗后与对照组相比,联合治疗组治疗后腹围与腹腔积液深度均明显减小,差异有统计学意义(t=-2.220,-2.155;P=0.031,0.036),而尿量则明显增加,差异有统计学意义(t=3.404,P=0.001)。与治疗前相比,联合治疗组治疗后脾静脉与门静脉内径都明显减小,差异有统计学意义(t=7.817,5.583;P=0.000,0.000)。两组患者治疗前后平均动脉压与心率均无明显变化。结论 前列腺素E1联合特利加压素在治疗肝硬化抗利尿性腹腔积液时疗效好于单用前列腺素E1,且对血压、心率影响较小。
中文关键词:肝硬化  特利加压素  血流动力学
 
Effect of Terlipressin Combined Prostaglandin E1 on Cirrhosis with Refractory Ascites
Abstract:Objective To explore the effect of Prostaglandin E1 combined terlipressin injection of liver cirrhosis with refractory ascites on relevant indexes,such as renal function, hemodynamics, heart rate, and so on. Methods 50 cases with liver cirrhosis, which accompanied by randomly divided into combined treatment group and control group. 25 cases in the refractory ascites combined treatment group, applied with terlipressin and Prostaglandin E1, while 25 cases in the control group, prescribed with Prostaglandin E1 only (Terlipressin 1mg,q8h,iv; Prostaglandin E1 10μg,qd,iv). The relevant indexes, such as urine volume, waist circumference, serum creatinine and so on, was compared between the two group. Results Before treatment, there was no significant difference in general information, such as weight, sex, albumin and so on. In the two group, BUN and SCr decreased after treatment, there existed significant difference (P<0.05). After treatment, compared with control group, SCr was decreased in the combined treatment group, which was statistically significant (t=-2.199; P=0.033). In the two group, ascites reduced and urine volume increased after treatment, and there existed significant difference (P<0.05). After treatment, compared with control group, abdominal circumference and ascites depth decreased in the combined treatment group, there was statistically significant (t=-2.220,-2.155;P=0.031,0.036),and the urine volume was increased (t=3.404,P=0.001). In the combined treatment group, the diameter of splenic vein and portal vein reduced, and the difference was statistically significant (t=7.817,5.583;P=0.000,0.000). In the two groups, there was no statistical significance existed in the MAP and HR. Conclusion Prostaglandin E1 combined with terlipressin in treating refractory ascites was superior to Prostaglandin E1 only, and has minor effects on blood pressure, heart rate.
keywords:Liver cirrhosis  Terlipressin  Hemodynamics
查看全文  查看/发表评论  下载PDF阅读器

京公网安备 11010502037822号